Home » Topics » BioWorld Science

BioWorld Science
RSS

Kazia Therapeutics initiates phase II trial of GDC-0084

March 29, 2018

pSivida announces acquisition of Icon Bioscience

March 29, 2018

MediciNova announces plans to study MN-166 for chemotherapy-induced peripheral neuropathy

March 29, 2018

Curadim licenses rights to Ube's LPA1 selective antagonist

March 29, 2018

Balixafortide/eribulin combination shows antitumor activity in metastatic breast cancer patients

March 29, 2018

Urovant initiates phase III trial of vibegron in overactive bladder

March 29, 2018

Lanadelumab submissions in E.U. and Canada accepted for review

March 29, 2018

EMA accepts BioMarin's MAA for pegvaliase to treat adults with PKU

March 29, 2018

Abide Therapeutics grants Celgene worldwide license for ABX-1772

March 29, 2018

Vifor Pharma grants Zeria license to develop and market Veltassa in Japan

March 29, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...